Endonovo Therapeutics (ENDV) Intangibles (2018 - 2023)
Endonovo Therapeutics has reported Intangibles over the past 9 years, most recently at $780260.0 for Q3 2023.
- Quarterly results put Intangibles at $780260.0 for Q3 2023, down 82.66% from a year ago — trailing twelve months through Sep 2023 was $780260.0 (down 82.66% YoY), and the annual figure for FY2022 was $1.3 million, down 71.88%.
- Intangibles for Q3 2023 was $780260.0 at Endonovo Therapeutics, down from $941988.0 in the prior quarter.
- Over the last five years, Intangibles for ENDV hit a ceiling of $4.5 million in Q1 2019 and a floor of $780260.0 in Q3 2023.
- Median Intangibles over the past 5 years was $3.2 million (2019), compared with a mean of $3.2 million.
- Biggest five-year swings in Intangibles: surged 116.96% in 2022 and later crashed 82.66% in 2023.
- Endonovo Therapeutics' Intangibles stood at $3.2 million in 2019, then fell by 20.18% to $2.6 million in 2020, then soared by 75.83% to $4.5 million in 2021, then plummeted by 71.88% to $1.3 million in 2022, then plummeted by 38.34% to $780260.0 in 2023.
- The last three reported values for Intangibles were $780260.0 (Q3 2023), $941988.0 (Q2 2023), and $4.5 million (Q1 2023) per Business Quant data.